In Reply We thank Dr Donti for her comments and the opportunity to clarify how blood pressure values from our study1 could be applied in a clinical setting.
We chose to stratify our analyses by baseline systolic blood pressure (SBP). We think that treatment effects by baseline SBP are more informative than achieved SBP because they better reflect the clinical situation. When a physician meets a patient and takes her blood pressure (BP), one wants to know if (additional) treatment to lower that pressure will reduce the risk of future cardiovascular events. One does not know, before treatment is initiated, what the achieved BP with any given treatment will be. Thus, translating our results into clinical practice becomes very easy. For primary prevention, patients with an SBP of 140 mm Hg or higher will likely benefit from treatment, whereas those with an SBP below 140 mm Hg will not.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Brunström M, Carlberg B. Questionable Conclusions Regarding Blood Pressure End Points—Reply. JAMA Intern Med. 2018;178(4):575–576. doi:10.1001/jamainternmed.2018.0029
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: